Objective-Myeloperoxidase, a heme enzyme that is present and active in human atherosclerotic lesions, provides a source for the generation of proinflammatory chlorinated reactants contributing to endothelial dysfunction. Modification of high-density lipoprotein (HDL) by hypochlorous acid/hypochlorite (HOCl/Oce Ϫ )-generated in vivo by the myeloperoxidase-hydrogen peroxide-chloride system of activated phagocytes-forms a proatherogenic lipoprotein particle that binds to and is internalized by endothelial cells. Elevated levels of plasma high-density lipoprotein (HDL) protect against atherosclerotic vascular disease. A broad spectrum of potent antioxidant and anti-inflammatory activities has been ascribed to native HDL. 11,12 However, oxidation/modification by HOCl alters the physicochemical and metabolic properties of anti-atherogenic HDL. [13] [14] [15] In vivo, apolipoprotein A-I, the major apolipoprotein of HDL, represents a selective target for MPO-catalyzed oxidation; a process apparently facilitated by MPO binding to apolipoprotein A-I. 16 Furthermore, significantly increased levels of 3-chlorotyrosine, a protein modification specific for the MPO-hydrogen peroxide-chloride-catalyzed oxidation, 17 were detected in association with apolipoprotein A-I recovered from serum of patients with cardiovascular disease. 16 In situ experiments revealed colocalization of specific epitopes derived from HOCl with apolipoprotein A-I in human atherosclerotic lesions and on endothelial cells lining the blood vessel. 8 MPO levels serve as a strong predictor of endothelial dysfunction in humans, 18 and MPO colocalizes with HOClmodified epitopes/(lipo)proteins on endothelial cells.
A nimal experimentation and clinical studies have provided convincing evidence that the known risk factors for cardiovascular disease can elicit a localized inflammatory response in the vasculature. The changes are most pronounced in endothelial cells and include oxidative stress, increased activation of endothelial signaling pathways, and the consequent adhesion, activation, and degranulation of leukocytes. The myeloperoxidase (MPO)-hydrogen peroxidesystem of stimulated leukocytes, primarily neutrophils, generates hypochlorous acid/hypochlorite (HOCl/Oce Ϫ ), a potent bacterial oxidant in vivo. 1 MPO and HOCl are emerging as critical modulators of vascular injury by promoting inflammatory arterial pathology and subsequent formation of mature plaques. MPO is present and active in human lesion material. 2 HOCl reacts with a wide range of biological substrates, including antioxidants, amines, sulfides, nucleotides, DNA, lipids, and (lipo)proteins. [3] [4] [5] HOCl-modified (lipo)proteins are present in human 6 -8 and rabbit lesions, 9, 10 and disease stage-dependent accumulation of HOCl-modified (lipo)proteins has been reported. 7 Elevated levels of plasma high-density lipoprotein (HDL) protect against atherosclerotic vascular disease. A broad spectrum of potent antioxidant and anti-inflammatory activities has been ascribed to native HDL. 11, 12 However, oxidation/modification by HOCl alters the physicochemical and metabolic properties of anti-atherogenic HDL. [13] [14] [15] In vivo, apolipoprotein A-I, the major apolipoprotein of HDL, represents a selective target for MPO-catalyzed oxidation; a process apparently facilitated by MPO binding to apolipoprotein A-I. 16 Furthermore, significantly increased levels of 3-chlorotyrosine, a protein modification specific for the MPO-hydrogen peroxide-chloride-catalyzed oxidation, 17 were detected in association with apolipoprotein A-I recovered from serum of patients with cardiovascular disease. 16 In situ experiments revealed colocalization of specific epitopes derived from HOCl with apolipoprotein A-I in human atherosclerotic lesions and on endothelial cells lining the blood vessel. 8 MPO levels serve as a strong predictor of endothelial dysfunction in humans, 18 and MPO colocalizes with HOClmodified epitopes/(lipo)proteins on endothelial cells. Native and modified lipoproteins have been reported to affect levels of nitric oxide (NO), 19 -24 an ubiquitous signaling molecule modulating a plethora of physiological responses including the propagation of a number of anti-atherogenic effects in the endothelium. 25 Here, we show that treatment of human umbilical venous endothelial cells (HUVECs) with HDL modified by HOCl impairs expression and activity of endothelial nitric oxide synthase (eNOS). The active component mediating this effect was found to be 2-chlorohexadecanal (2-ClHDA) formed via HOCl-mediated oxidative attack of HDL-associated plasmalogen.
Materials and Methods
A detailed Materials and Methods section on lipoproteins, 8, 13, 26 preparation of lipid micro-emulsions and acid hydrolysis of lipoprotein-associated lipids, 26, 27 synthesis, derivatization, and quantitation of 2-ClHDA by gas chromatography-mass spectrometry, 28 -30 cell culture experiments, 24 neutrophil stimulation, 9,27 eNOS activation assays, 24, 31 Northern blot analysis and mRNA stability, 24 Western blotting, 24 and immunofluorescence is available online at http://atvb.ahajournals.org.
Results and Discussion
The effect of HDL to modulate NO release from endothelial cells has been investigated by several groups. 32 Here, we show that HDL modified with HOCl concentrations that are easily achieved under acute inflammation 13, 33 caused a marked, sustained, concentration-dependent, and timedependent decrease of NO production in stimulated HUVECs as measured by the conversion of L-arginine to L-citrulline ( Figure 1A to 1C) . To confirm the functional significance of these findings, we assessed the effects of HOCl-HDL on the production of cGMP, a second messenger formed via activation of soluble guanylate cyclase by NO. As expected, HOCl-HDL caused a marked reduction of cellular cGMP production ( Figure 1A and 1B). Of note, HOCl-HDL did not affect endothelial cell viability or alter cell growth behavior as determined by trypan blue exclusion and incorporation of 14 C-labeled amino acids. Furthermore, no evidence of endothelial cell apoptosis was seen under the experimental conditions described (data not shown).
The efficacy of NO biosynthesis critically depends on the correct compartmentalization of eNOS in specific intracellular membrane domains, ie, Golgi complex and plasmalemmal caveolae. 34, 35 We previously reported that low-density lipoprotein (LDL) modified by reagent HOCl inhibits NO synthesis in HUVECs via an intracellular dislocalization of eNOS without altering eNOS protein expression and without altering myristoylation or palmitoylation of the enzyme. 24 Here, we show that coincubation of HUVECs with HOCl-HDL also leads to changes of intracellular eNOS distribution including translocation from the plasma membrane and disintegration of the perinuclear location ( Figure 2A ). But in contrast to HOCl-LDL, HOCl-HDL further decreased eNOS expression on mRNA and protein level ( Figure 2B and 2C). HOCl-HDL also induced a marked downregulation of eNOS protein expression when cells were incubated in the presence of DRB, a transcription inhibitor ( Figure 2D ). When cells were incubated with cycloheximide, an inhibitor of protein synthesis, HOCl-HDL had no significant effect indicating that a post-translational destabilization of eNOS is not involved; thus, it is conceivable that downregulation of eNOS is a post-transcriptional event caused by decreased stability of eNOS mRNA. In line with these observations, NO biosynthesis in cell lysates in the presence of saturating concentrations of substrate and cofactors 31 was also decreased (Figure 2D). Of note, HOCl-HDL-induced decrease in L-citrulline formation was much more pronounced in ionomycinstimulated intact cells than in cell lysates, suggesting that the combination of decreased eNOS protein content and eNOS mislocalization elicits the maximal inhibitory effect.
Apolipoprotein A-I represents a preferential target for HOCl attack. 13, 16, 36, 37 Treatment of HDL by HOCl leads also to consumption of unsaturated fatty acids. 13 Furthermore, the formation of lysophospholipids from unsaturated phosphatidylcholines after HOCl treatment has been reported. 38 To identify the constituent of HOCl-HDL that interferes with eNOS biosynthesis, HUVECs were treated either with the lipoprotein-lipid extract (a micro-emulsion of isolated lipids) or with the remaining apolipoprotein moiety. Lipids extracted from HOCl-HDL inhibited ionomycin-induced L-citrulline synthesis in intact cells ( Figure 3A ) and eNOS protein expression ( Figure 3B ) to a similar extent as observed with intact HOCl-HDL. The apolipoprotein fraction of HOCl-HDL showed no inhibitory activity (data not shown). To further identify the active lipid component of HOCl-HDL, HDL-associated lipids were separated and modified with HOCl; an equivalent amount of these products being present in 90 g HDL-TC/mL was used to treat HUVECs. Among the modified lipid subclasses tested, only the HOCl-modified plasmalogen fraction suppressed eNOS protein levels ( Figure  3C ). To further strengthen the potential role of these ether phospholipids, total HDL lipids were depleted from the plasmalogen fraction by acidic hydrolysis. 27 In line with data shown in Figure 3C , total HDL lipids modified with HOCl suppressed eNOS protein levels, whereas the plasmalogendepleted lipid fraction, after modification with HOCl, was without effect on eNOS levels ( Figure 3D ).
Plasmalogens, localized in the plasma membranes of mammalian cells and present in lipoproteins, 39 are considered to be antioxidants because the vinyl ether bond is susceptible to attack by oxidants. 30 Recent findings revealed that the vinyl ether bonds of plasmalogens are highly accessible molecular targets of the membrane-permeable, reactive chlorinating species generated by the MPO-hydrogen peroxide-chloride system; as a result, lysophosphatidylcholine and ␣-chlorinated fatty aldehydes are formed. 30 Thukkani et al 29 have shown that 2-ClHDA is formed as the main ␣-chloro fatty aldehyde from cellassociated plasmalogen. In another report, these authors demonstrated that 2-ClHDA is also generated when LDL was coincubated with stimulated monocytes. 40 Therefore, we first tested whether HOCl (added as reagent) targets HDL-associated plasmalogen, leading to 2-ClHDA formation. For external quantification, 2-ClHDA was synthesized and characterized by gas chromatography-mass spectrometry analysis. Analysis of PFB oximes from synthetic 2-ClHDA and 2-ClHDA isolated from lipid extracts from HOCl-HDL ( Figure I , available online at http://atvb.ahajournals.org) showed identical results regarding retention time of 7.25 minutes and 7.15 minutes (an expected C16:0 isoform), 29 as well as full scan spectra ( Figures II and III , available online at http://atvb.ahajournals.org). Prominent fragmentation peaks occurred at m/z 196 and m/z 288/290. Additional peaks from lipid extracts obtained from HOCl-HDL could be identified as dichlorinated hexadecanal (7.42 minutes), monochlorinated C18:1 fatty aldehyde (7.70 minutes), and a monochlorinated C18:0 fatty aldehyde (7.77 minutes). 2-ClHDA could not be detected in native HDL ( Figure I ) or in plasmalogen (data not shown). When plasmalogen-enriched HDL was subjected to HOCl-treatment, 2-ClHDA concentrations increased several-fold compared with HOCl-HDL (data not shown).
The plasmalogen content in HDL is Ϸ100 nmol/mg TC. 42 After HOCl-modification of HDL (oxidant:lipoprotein molar ratio of 100:1) Ϸ80% of the total plasmalogen fraction contributes to 2-ClHDA formation ( Figure 4A ). HOCl-modification of HDL (oxidant:lipoprotein molar ratio of 25:1 and 100:1; 90 g TC/mL) resulted in the generation of Ϸ4 to 6.5 mol/L 2-ClHDA. These levels are close to the concentration range of 2-ClHDA reported to be present in atherosclerotic lesions (10 mol/L), a concentration that is almost 1400 times that of normal aorta samples. 41 The plasmalogen content in LDL was found to be Ϸ74 nmol/mg TC, respectively. 42 HOCl treatment of LDL (oxidant:lipoprotein molar ratio of 400:1) also led to generation of 2-ClHDA (data not shown). However, only up to 22% of LDL-associated plasmalogen was consumed after HOCl treatment.
Second, we tested whether HOCl-generated by the MPOhydrogen peroxide-chloride system-will target the plasmalogen moiety of HDL, leading to the generation of 2-ClHDA. The predominant in vivo sources for MPO released during the oxidative burst are neutrophils and monocytes, in which MPO comprises 5% and 1% in the total protein content, respectively. Here, we show that considerable amounts of 2-ClHDA were generated via the active enzymatic pathway of stimulated neutrophils coincubated with native HDL (Figure 4A ). In line with studies performed on monocytes, 40 the presence of the MPO inhibitor sodium azide ( Figure 4A ) or the HOCl scavenger methionine (data not shown) prevented 2-ClHDA formation after phorbolester activation of neutrophils.
To clarify whether 2-ClHDA directly alters eNOS expression and NO biosynthesis, 2-ClHDA was used in cell culture experiments. We present 4 lines of evidence that plasmalogen-derived 2-ClHDA is the lipid component mediating the inhibitory effects of HOCl-HDL on eNOS protein expression and activity. First, 2-ClHDA strongly inhibited ionomycin-stimulated NO formation ( Figure 4B ). Importantly, when cells were stimulated with the physiological agonist thrombin, the inhibitory activity of 2-ClHDA was even more pronounced. Second, as determined by confocal microscopy, 2-ClHDA affected intracellular eNOS targeting already at 2 mol/L ( Figure 4C ). Higher concentrations of 2-ClHDA (5 and 10 mol/L) led to a complete translocation of eNOS from the plasma membrane and disintegration of the perinuclear location. Third, 2-ClHDA-at concentrations of 5 mol/L and higher-attenuated eNOS protein expression ( Figure 4D ). Fourth, 2-ClHDA (10 mol/L) decreased eNOS mRNA expression in the presence of DRB ( Figure 4E ), indicating that eNOS mRNA stability is impaired. Of importance, effects of 2-ClHDA on eNOS protein expression were observed at threshold concentrations of 5 mol/L, whereas disruption of eNOS localization was already observed at 2 mol/L. This explains why LDL after HOCl treatment had no effect on eNOS protein expression, 24 as 2-ClHDA concentrations generated were calculated to be lower under our experimental conditions. MPO gene variations may be considered as determinants of the atherosclerotic progression. 43 Elevated levels of leukocyte and blood MPO are predictive risk factors for endothelial dysfunction 18 and coronary artery disease in humans. 44 Moreover, products of MPO-mediated reactions are present in human atherosclerotic lesions 6 -8,16,17,41,45 and MPO has been identified as an HDL-associated protein within human atheroma. 16 Thus, it is conceivable that the MPO-hydrogen peroxide-chloride system acts as a platform for the formation of inflammatory markers generated during the initiation and progression of cardiovascular disease. HOCl-HDL is bound and internalized by HUVECs. 46 Also MPO-released by intraluminal degranulation of activated phagocytes-binds to and transcytoses across the endothelium 47 and may directly modulate vascular inflammatory responses by regulating NO bioavailability. 48 We show that 2-ClHDAgenerated by reagent HOCl and the MPO-hydrogen peroxidechloride system of activated phagocytes-is a strong modulator of eNOS expression and activity. Normally, eNOS produces a tonic amount of NO, which is responsible for the homeostasis between the endothelium and surrounding tissues. Our data indicate that HOCl-mediated generation of chlorinated fatty aldehydes from lipoprotein-associated plasmalogens could represent a dominant pathway contributing to pathophysiological changes, ultimately leading to inflammatory responses, endothelial dysfunction, and tissue injury. 
